Moreover, GBM-derived NLGN3 has an oncogenic function and can induce cancer stem cell (CSC) properties within GBM [36], which is significant because clinical evidence suggests that an increased number of CSCs may contribute to the failure of conventional therapies. This evidence concerns the gene NLGN3 and cancer.